Category Business

WISE Closes Oversubscribed €30 Million Series D Round, Adds ENEA Tech and Biomedical as Strategic Investor

WISE Raises €30 Million in Oversubscribed Series D Round to Advance Heron Spinal Cord Stimulation Lead and Expand Neurotechnology Platform WISE S.p.A., an Italian medical device company developing advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface applications, has completed…

Read MoreWISE Closes Oversubscribed €30 Million Series D Round, Adds ENEA Tech and Biomedical as Strategic Investor

Simulations Plus to Join Altaris in Approximately $375 Million Buyout Deal

Simulations Plus Agrees to $375 Million Acquisition by Altaris, Signaling New Chapter in AI-Driven Drug Development Simulations Plus, Inc., a recognized leader in model-informed drug development and artificial intelligence-enabled pharmaceutical research solutions, has entered into a definitive agreement to be…

Read MoreSimulations Plus to Join Altaris in Approximately $375 Million Buyout Deal

Cellares Secures Additional $50 Million Investment, Bringing Series D Round to $327 Million

Cellares Secures Additional $50 Million Investment, Expanding Series D Financing to $327 Million to Accelerate Global Cell Therapy Manufacturing Network Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO) dedicated to advancing automated cell therapy production, has announced a…

Read MoreCellares Secures Additional $50 Million Investment, Bringing Series D Round to $327 Million

Rallybio and Avenzo Therapeutics Merge to Accelerate Next-Generation Cancer Treatments, Backed by $215 Million Private Financing

Rallybio and Avenzo Therapeutics Announce Merger Backed by $215 Million Financing to Advance Next-Generation Oncology Pipeline Rallybio Corporation and Avenzo Therapeutics have entered into a definitive merger agreement that will create a publicly traded oncology-focused biotechnology company with a portfolio…

Read MoreRallybio and Avenzo Therapeutics Merge to Accelerate Next-Generation Cancer Treatments, Backed by $215 Million Private Financing

Lantern Pharma Announces First Quarter 2026 Financial Results and Corporate Updates

Lantern Pharma Reports First Quarter 2026 Results While Expanding AI-Driven Oncology and Commercial AI Platform Strategy Lantern Pharma reported operational highlights and financial results for the first quarter ended March 31, 2026, outlining continued progress across its precision oncology pipeline,…

Read MoreLantern Pharma Announces First Quarter 2026 Financial Results and Corporate Updates